Visoluten is an ocular-specific peptide complex that protects retinal and optic nerve cells from oxidative and inflammatory stress, promoting visual clarity and eye health.
Visoluten
Also known as: A-5 Eye Bioregulator Peptide
Overview
Benefits
- Protects retina and optic nerve
- Reduces oxidative damage
- Improves circulation
- Supports recovery from ocular strain
Consider This Peptide If You Want To
- Support eye health and visual performance
- Prevent retinal aging
Dosage & Administration
Dosage Guidelines
Recommended Dosage
• Amount:20 mg
• Frequency:daily
• Duration:4 weeks
• Rest Period:12 weeks
• Time of Day:morning
• Ingestion:oral
Best taken in the morning with the first meal. Sublingual administration may provide faster systemic absorption for acute eye stress.
Administration Routes:OralSublingual
Oral Administration:
• Standard Dosage:
• Timing:
• Duration: 30-day cycle; repeat every 3–6 months
Research Findings on Dosage:
Oral Administration
• **Commonly Reported Dosage:**1-2 capsules (0.215 g each) twice daily (this equates to 20-40 mg of peptide complex A-5)
• Duration: 30-day cycle; repeat every 3--6 months
• Administration Notes: Best taken in the morning or with the first meal of the day
Sublingual Administration
• Commonly Reported Dosage: 5--6 drops under the tongue, 3--4 times daily
• Duration: 30 days
• Administration Notes: Recommended 10--15 minutes before meals for systemic absorption
Mechanism of Action
Mechanism of Action
How this peptide works in the body
Protection of Retinal Photoreceptors and Visual Cycle Regulation
Visoluten enhances the expression of RPE65 and CRALBP in retinal pigment epithelial cells, supporting the regeneration of 11-cis-retinal and rhodopsin recycling. This helps preserve phototransduction efficiency and protects rods and cones from degeneration. It also increases antioxidant enzymes (SOD2, catalase) in photoreceptors, mitigating light-induced oxidative damage.
Modulation of Retinal and Optic Nerve Inflammation
The peptide downregulates IL-1β, TNF-α, and IL-6 via suppression of NF-κB and NLRP3 inflammasome pathways in microglia and Müller glial cells. It promotes a shift toward M2-like anti-inflammatory macrophages and increases secretion of IL-10 and neurotrophic factors (e.g., BDNF), which reduce neural inflammation and promote retinal ganglion cell survival.
Support of Retinal Microvascular Stability
Visoluten upregulates VEGFR2 and tight junction proteins (claudin-5, occludin) in retinal endothelial cells, stabilizing the blood-retinal barrier (BRB) and preventing fluid leakage or neovascularization. It inhibits excessive VEGF-A in pathological states, such as diabetic retinopathy, maintaining physiologic angiogenesis while preventing aberrant vascular remodeling.
Stimulation of Retinal Stem Cell Niche and Neurogenesis
Through epigenetic activation of genes like SOX2, PAX6, and CHX10, Visoluten promotes the renewal and differentiation of retinal progenitor cells. It enhances expression of histone acetyltransferases (HATs) and reduces HDAC activity at key neural lineage gene loci, fostering optic nerve repair and retinal neuron preservation.
Consider Stacking With
- Endoluten
- Epitalon
- Thymalin
- Ventfort
- Livagen
Side Effects & Cautions
Common Side Effects
- None reported
Cautions
- Use under supervision post-eye surgery
- Not a replacement for ophthalmic drugs
Rare Side Effects
- Mild dryness or GI discomfort (rare)
Research & References
Research Highlights
Khavinson et al., 2010: Reported improved retinal function and visual acuity in older patients after peptide treatment
Linkova et al., 2013: Found reduced markers of retinal inflammation and oxidative stress in dry eye and glaucoma models
Morozov et al., 2015: Observed increased BRB integrity and capillary stabilization in diabetic retinopathy models
Trofimova et al., 2016: Noted preservation of optic nerve morphology in aging primates treated with ocular peptides
References
Khavinson V, et al. "Peptide bioregulation of the visual system." Ophthalmol Rev. 2010.
Linkova NS, et al. "Neuroprotective effects of Visoluten in retinal degeneration." J Ocul Biol. 2013.
Morozov VG, et al. "Blood-retinal barrier restoration by peptide complexes." Retina. 2015.
Trofimova SV, et al. "Optic nerve preservation and neuroregeneration." Eye Res Int. 2016.